Bausch Health: a 54% cash yield in 2026, about 2% by 2030

Bausch Health guides its parent company, everything except the Bausch + Lomb eye-care business, to $1.40 to $1.475 billion of adjusted operating cash flow in 2026. The whole company, 373.99 million shares at $6.04, is worth $2.26 billion on the stock market. On my normalized estimate of $1.3 billion of parent cash, that is a 54.5% yield, the kind of number a screener flags in green. Then read the debt note. The parent owes $15.1 billion of principal, I estimate its cash interest at $1.35 billion a year, and a drug that is about 22% of consolidated revenue is about to be repriced by Medicare.

At the October 9 close, the shares trade 36.9% below my triangulated Base value of $9.57. The Bear value is $0.00 and the Bull value is $29.23, and a second method puts the Bull case as high as $49.16, so the upper end is disputed. The required margin of safety (MOS), the discount to fair value I need before buying, is 70%. The framework caps a practical requirement at 60% and prefers a watchlist verdict to a deceptively precise price above that, so no maximum buy price is issued. The question is not whether 2026 is a good year. It is how much of that cash is still there after 2028.

Route: SF-09 healthcare. Subtype: mature specialty pharmaceuticals and aesthetic devices with a controlling listed eye-care investment, not a pre-revenue drug developer. Economic classification: Standard (3/12). Primary method: sum of the parts, with the parent valued at a multiple of normalized EBITDA after stock compensation and the Bausch + Lomb stake added at a marked market value. Secondary method: a patent cliff free cash flow model of the parent, ten years plus a terminal value. Values are present fair value estimates, not 12 month price targets.

What Bausch Health is

The parent comprises four businesses: Salix, the gastrointestinal drug franchise built around Xifaxan; International, which sells pharmaceuticals and consumer products outside the US; Diversified, a portfolio of mature brands; and Solta, aesthetic devices. Bausch + Lomb (BLCO), the eye-care company, is listed separately. Bausch Health holds 310,449,643 BLCO shares, about 87% of the total, and consolidates it in its reported accounts. BLCO still has its own equity holders, $5,128 million of debt and $367 million of cash, so I do not treat BLCO's cash flow as Bausch Health's. The parent is valued on its own, and the BLCO stake is added at its quoted price after a haircut for the cost of turning it into cash.

Xifaxan is the concentration. The company's filings put it at roughly 85% of Salix sales. On Salix first half revenue of $1,397 million, that indicates about $1,187 million, or 22.1% of consolidated revenue. Annualized, it is about $2.4 billion, roughly 44% of the parent's guided revenue. The 85% mix is approximate and the product sales are not reported exactly, so treat these as orders of magnitude. Three dates define the risk:

• January 2027. Under Medicare price negotiation, the maximum fair price of Xifaxan is $1,000 per 30-day supply, against a 2024 list price of $2,696 per 30-day supply, a 63% reduction in list price. That is not a 63% cut in company net sales. Actual payer mix, rebates and net revenue per patient are not disclosed in enough detail for me to calculate the real hit.
• January 2028. A settlement with Actavis (Teva) permits specified generic options, with an earlier entry if another qualifying generic launches first. Authorized generic economics could keep some cash with the company, but the amount is not public.
• October 2029. The injunction on the first Norwich application, upheld by the Federal Circuit in April 2024, blocks FDA approval of that application until October 2029. It is not exclusivity against every generic. According to the second quarter 10-Q, other proceedings, including Norwich II and an Amneal case, are unresolved.

The latest quarter

The second quarter looks strong on the headline lines. Net income attributable to Bausch Health was $258 million, against a first half loss of $1,165 million. The gap is a single non-cash item: a $1,426 million goodwill impairment recorded in the first quarter. It is not a cash expense, but it shows that asset values were marked down. Goodwill fell from $11,271 million to $9,793 million.

The July 29 guidance for 2026 is consolidated revenue of $10.79 to $11.04 billion, split into $5.35 to $5.50 billion for the parent and $5.44 to $5.54 billion for Bausch + Lomb. Adjusted EBITDA is guided at $4.05 to $4.175 billion in total: $3.025 to $3.100 billion for the parent and $1.025 to $1.075 billion for Bausch + Lomb. The parent adjusted operating cash flow guide is $1.40 to $1.475 billion. The historical adjusted EBITDA above is after noncontrolling interests, so it is not comparable with the guided totals. Research and development is 6.25% of first half revenue, which fits a commercial drug and device company rather than an early-stage biotech.

Why cash after all interest is the metric

Management guides to EBITDA, and EBITDA is the wrong place to stop for a company with this much debt. The right question is how much cash reaches the common shares after every contractual cost. Two details matter. First, part of the interest on older notes is charged against recorded debt premiums and appears in financing cash flows, not operating cash flow, so conventional free cash flow (operating cash flow minus capital spending) flatters the result. Second, the company adds back stock compensation, which is a real cost to owners.

For the first half of 2026, the 10-Q describes $66 million of premium reduction on older secured notes and $47 million on the 2032 notes, $113 million in total. The earnings reconciliation subtracts $100 million. I have not been able to reconcile the $13 million gap, and I carry both numbers as a range.

These are cash definitions, not a dividend pool. Acquisitions, licensing, contingent payments, tax withholding on equity awards and fees can reduce liquidity further. The company's own second quarter parent figures show the same pattern: adjusted operating cash flow of $471 million is below reported parent operating cash flow of $517 million, because $56 million of interest charged against debt premium is deducted. So I do not treat every adjusted measure as inflated, but I do not treat any of them as owner cash either.

The consolidated numbers also include all of Bausch + Lomb's cash. Normalized to the parent for 2026, my estimate of levered cash is $1,300 million:

Premium interest is not deducted again from that starting point. The $1,300 million is a 2026 figure and I do not carry it past the Xifaxan cliff.

For the enterprise value methods I start from EBITDA, not cash. The guided parent adjusted EBITDA midpoint is $3,062.5 million. I deduct $150 million of recurring items the company adds back, giving $2,912.5 million. For scale, consolidated first half add-backs other than impairments and stock pay were about $85 million (restructuring and transformation $33 million, acquisition costs $22 million, litigation $16 million, other $14 million and smaller items), which is $170 million annualized and includes Bausch + Lomb.

Then comes stock compensation. Consolidated share-based compensation was $106 million in the first half, of which Bausch + Lomb recorded $72 million, so about $34 million, or $68 million a year, belongs to the parent. That is my estimate of the parent's run rate and it is deducted from EBITDA: normalized EBITDA after SBC is $2,844.5 million. Bausch + Lomb's stock pay is already inside the quoted price of its shares, so charging it again to the parent would count it twice.

Shares, dilution and the debt

The share bridge starts with 373,990,561 common shares outstanding on July 24, 2026. Add 12.716 million time-based restricted stock units and 4.713 million performance units at target and you reach 391.4 million, before options. The remaining 4.796 million options need exercise-price-specific treatment. Counting every option and the maximum 9.426 million performance shares would give 400.9 million, which is a ceiling, not an expected count. I use 395 million diluted shares in every main scenario, a conservative allowance and not a filed count. Reported second quarter weighted diluted shares were 378.1 million, and first half shares were 373.9 million because awards are excluded in a loss period. A separate stress with 450 million shares, including hypothetical proceeds, is in the sensitivity section.

The consolidated debt on the balance sheet, $20,741 million, includes net premiums, discounts and issuance costs, so it is not principal due. Parent net debt is 4.46 times the guided EBITDA midpoint, 4.69 times normalized EBITDA before stock pay and 4.80 times normalized EBITDA after it. These are analytical ratios, not covenant calculations.

The schedule sums to $15,111 million. The 2028 to 2030 wall, $7,960 million, lands on top of the patent erosion. Parent cash of $1,458 million covers the 2027 maturities 2.17 times but only 62.7% of 2028. That is not a solvency test: cash is also needed for working liquidity and interest, and Bausch + Lomb's cash is not automatically available to the parent. Refinancing moves the dates and does not erase the principal. Available liquidity in October and exact covenant headroom are not available to me.

One more constraint on the stake. The 2025 annual report describes 211,963,893 Bausch + Lomb shares pledged under the 2025 financing, about 68.3% of the holding. That is the documented baseline, not a verified October collateral list. A tax-free spin-off or a sale of the stake is not an unconditional distribution to Bausch Health shareholders.

Primary valuation: parent EV to EBITDA after stock compensation, plus the Bausch + Lomb stake

The parent is valued on its normalized EBITDA after SBC at 3.0x, 4.5x and 6.0x in the Bear, Base and Bull cases. These multiples are my assumptions about how long the cash lasts, not measured peer medians; I had no verified peer table. The low Base multiple already reflects a finite Xifaxan life and uncertain replacement, so no premium from ordinary diversified pharma is imported. The formula is: common equity equals normalized parent EBITDA after SBC times the multiple, plus the Bausch + Lomb stake after its haircut, minus parent net debt, minus a $200 million reserve for legacy claims, with a floor of zero, divided by 395 million shares.

The Bear zero is a modeled wipeout or restructuring outcome, not a claim that the shares must trade at zero today. Two bridge rules matter. BLCO's quoted price is already an equity value after its own debt, so I subtract only the parent's net debt. Subtracting consolidated net debt would deduct BLCO's debt twice. Conversely, adding BLCO's operating value without its debt and minority holders would overstate the stake. I also grant no unverified debt reduction since June 30 and no control premium on the stake, and the 10% haircut is the only deduction for monetization friction.

Sensitivity: value per share, Base EBITDA after SBC

One full turn of the multiple moves the value by about $7.20 a share, because the multiple works on an EBITDA that sits mostly above the debt. A $1 change in BLCO's share price moves the Base by $0.71 a share, and a $1 billion change in parent operating value moves it by $2.53. With this much debt, small errors in enterprise value become large errors in equity value.

Pipeline: counted at zero

I give the pipeline no value in the main model. RED-C gets zero because both Phase 3 studies missed their primary endpoint. Larsucosterol, acquired from DURECT with up to $350 million of sales milestones, entered a registrational Phase 3 in January 2026 and has breakthrough designation, which is not approval. Amiselimod is in Phase 2 and regulatory evaluation, which does not establish a launch date. As an illustration only, a finite-life risk-adjusted value of larsucosterol, with sales from 2029 to 2038, no terminal value and two assumed milestones of $175 million in 2033 and 2036 (the actual triggers are not established), comes out like this:

Every input is my estimate, including the 2029 launch, and the probabilities are deliberately below the generic Phase 3 rule of thumb because asset-specific evidence is thin. Adding the net value to the main model would double charge the development costs that already sit in operating forecasts, and adding only the commercial upside would overstate it. Even the Bull illustration is about $1.24 a share. It does not change the answer.

Secondary valuation: patent cliff cash flow model of the parent

The second method forecasts the parent's cash year by year and discounts it, so it tests durability and not another multiple. It uses unlevered free cash flow (FCFF): cash after operating costs, taxes, reinvestment and working capital, before interest. For 2027 the Base bridge is $3,062.5 million of EBITDA, minus $150 million of recurring costs, $250 million of cash taxes, $100 million of total reinvestment and $162.5 million of working capital and other items, which gives $2,400 million. These allowances are mine and are not a management breakdown. I then deduct the $68 million of parent stock pay, so 2027 Base FCFF is $2,332 million.

The valuation date is October 11, so the rest of 2026 sits 0.222 years out and each later year one year further. The discount rates are 14%, 12% and 10% for the Bear, Base and Bull cases, with terminal growth of 0%, 0% and 1%. June 30 net debt is retained because an October balance is not available, which avoids crediting unverified debt reduction but could overstate liabilities if cash built up in the third quarter. The same stake, debt and reserve bridge as in the primary method applies.

The Base cash flow falls 30.0% in 2028 and another 21.4% in 2029 before a modest recovery. That represents Xifaxan pricing and generic erosion partly offset by the rest of the business; the drug-by-drug split is not available. The terminal value is 30.3% of the Base EV and 44.0% of the Bull EV. The Base assumes neither a perpetual monopoly nor automatic pipeline replacement. The 12% rate is a required return I chose, not a measured cost of capital.

This method is independent of the multiple on the core business, but not of the Bausch + Lomb stake or the creditor claims, which are the same in both. It is also not a valuation of Bausch + Lomb itself. A current fundamental model of Bausch + Lomb is missing, which is why the stake price and haircut stresses matter.

Sensitivity: Base value per share

A 20% cut in operating cash takes the Base from $10.70 to $3.70, a 65% loss of equity value, and a 40% cut wipes it out. The loss is nonlinear because the debt does not shrink with the cash.

History and growth diagnostics

A synchronized multi-year history of the parent's EV to EBITDA, with a consistent split of Bausch + Lomb, debt premiums and minorities, is not available. The old Valeant perimeter and the post-IPO Bausch Health perimeter cannot be compared, so I do not invent a historical mean or a peer premium. The historical layer gets no weight.

A forward price to earnings to growth (PEG) ratio is not available either. I have no same-date positive adjusted EPS forecast and growth rate, and GAAP earnings distorted by an impairment cannot be divided by adjusted growth. Cheap pre-cliff adjusted earnings can also give a misleadingly low PEG even when EPS is positive. The patent cliff distortion flag is high, the accounting basis mismatch flag is high if the two are mixed, and the PEG gives no growth premium and sets no value.

The cash history is short. From the annual report, reported operating cash flow minus capital spending minus premium interest charged outside operating cash flow was $535 million in 2023, $965 million in 2024 and $727 million in 2025. That is a 16.6% a year increase over two years, but a 24.7% fall in the last year, so the series is not steady. It also includes 100% of Bausch + Lomb's cash and excludes acquisitions and contingent payments. Per year-end common share the same measure is $1.465, $2.624 and $1.962, and the share count grew 0.72% a year. A normalized three to five year free cash flow growth rate and a properly diluted per-share series are not available.

For the twelve months to June 2026, operating cash flow of $1,800 million, minus $369 million of capital spending and $212 to $225 million of premium interest, leaves $1,206 to $1,219 million, 53.4% to 54.0% of the basic market value of $2,258.9 million. That is a consolidated diagnostic yield, not an owner yield. My forward parent figure is $1,300 million over $2,386 million of market value on 395 million shares, or 54.5%, and I rate its reliability as low.

The yield does not last. Using the Base FCFF before stock pay and a constant cash interest allowance of $1,350 million a year, which is my estimate, with no tax shield credit, levered cash is about $1,050 million in 2027 and $50 million in 2030. That is $2.66 a share falling to $0.13, a 63.8% a year decline, or a 2.1% forward yield on the current price. Stock pay is not deducted here because this test is about cash. It is a stress proxy, not an equity model and not a dividend forecast.

On illustrative parent revenue of $5,400 million in 2027 and $4,200 million in 2030, which are my numbers and not guidance, the cash margin falls from 19.4% to 1.2%. In 2026, cash is 44.6% of normalized EBITDA before stock pay. A high near-term yield and weak post-cliff coverage live in the same company. Growth quality is uncertain and acquisition affected. These diagnostics do not set the Base, the MOS or the verdict.

Valuation triangulation

The two Base values are 11.1% apart, inside the 20% convergence band. I take the lower, $9.57, as a cautious central anchor and give no weight to history or PEG. A 50/50 average would be $10.13. Both Bear cases leave a negative residual before the zero floor, so the divergence formula is undefined for them, and I do not present two zeros as 0% divergence.

The Bull values diverge by 50.8%, a flag. The cash flow model's durable recovery and terminal value support far more than a 6x multiple. I do not average the two. I publish $29.23 as the conservative Bull anchor and show $49.16 as a disputed upper outcome. That lowers Confidence and adds 5 points to the MOS. The methods also share the same stake and debt bridge, so their agreement on the Base is partly built in. And the near-term cash yield cannot confirm the Base when its own numerator is what the cliff threatens.

What is the market already pricing in?

The market capitalization on actual shares is 373.99 million times $6.04, or $2,258.9 million. Adding parent net debt of $13,653 million and the $200 million reserve, and subtracting the Bausch + Lomb stake after its haircut ($4,833.7 million), implies a parent operating value of $11,278 million.

The price does not assume failure. It assumes that roughly 15% of the Base cash, including the long tail, never arrives, or that the stake is worth less than the haircut implies, or that litigation and financing cost more. The same price could reflect higher required returns, a lower stake value or a dilutive raise, so this is not a unique forecast. What it rules out is the idea that the market has missed the cliff. The question for new money is whether 15% is enough of a cushion when a 20% cut in cash takes the DCF to $3.70.

Bear, base and bull scenarios

These are scenarios, not probabilities and not one-year targets. I publish no probability-weighted return because I cannot support the weights. The Bull case adds no proceeds from selling the same stake and no pipeline upside. The scenarios are not the whole downside, and these tests change one assumption at a time:

One more mechanical stress: an extra 100 basis points on roughly $2,970 million of unhedged variable-rate parent principal would cost about $29.7 million a year before tax. That is arithmetic, not a view on October refinancing terms. No future debt reduction is added on top of the enterprise cash flows, because using the same cash both to repay debt and to distribute would count it twice.

The bear case to take seriously is not the zero. It is the 20% cut to cash that leaves $3.70, which is 39% below today's price in a scenario that still has the company paying its debt. A full 2027 to 2028 refinancing at higher cost would do the same job without any change in operations.

How the buy price is set

A Confidence score of 10/25 is grade D, which starts the MOS at 50%. I add 5 points for financial leverage, because the equity is a thin residual behind the creditors, 10 for binary legal and regulatory exposure beyond the scheduled patent erosion, and 5 because the two methods disagree by more than 30% in the Bull case. Concentration and opacity add nothing extra, since they are already in the cliff assumptions and the Confidence score. The uncapped requirement is 70%, above the 60% practical maximum.

Above that ceiling, the framework prefers a no-buy or watchlist verdict to a precise-looking price. No maximum buy price and no buy zone are issued. For orientation only, 70% below $9.57 is $2.87, and a 50% to 60% requirement, which would need the Confidence grade to improve to C and the overlapping risks to shrink, would give $3.83 to $4.79 on an unchanged Base. Neither is a price alert. At $6.04, the 36.9% discount to Base is not enough even for the lower, hypothetical range. Reactivation needs a funded maturity plan, an updated cash and share bridge and a better quantified post-cliff cash flow.

Dividend and capital return

Bausch Health is not an income stock. Neither valuation assumes a common dividend, and cash goes to debt service first. A subsidiary's value is not the parent's distributable cash. A dividend from Bausch + Lomb would be counted once and only after its own debt and capital needs, and I assume none. No buyback is credited.

Reasons to own BHC

• The cash is real in 2026. Guided parent adjusted operating cash flow is $1.40 to $1.475 billion, and my normalized estimate of $1.3 billion is 54.5% of the market value.
• A separately quoted asset. The 310.4 million Bausch + Lomb shares are worth $5.37 billion at $17.30, about 2.4 times Bausch Health's whole market capitalization.
• The price is low against the operations. It implies 3.97x normalized EBITDA after stock pay, below my 4.5x Base multiple.
• Diversification beyond Xifaxan. International, Diversified and the Solta device business provide cash that does not depend on one drug.
• Time was bought. The 2025 refinancing moved some maturities out, and only $673 million of parent principal falls due in 2027.

The Bull case of $29.23 includes none of the pipeline. It is what happens if erosion is slower, the stake can be monetized and financing stays open. An investor needs to accept a real chance of permanent loss, and to explain why their view of post-cliff cash is better supported than the cautious one.

What could go wrong?

• Thesis breaker: earlier or deeper Xifaxan erosion and no way to refinance or monetize assets without harming common equity. A 40% cut to Base cash flow removes all the equity in the cash flow model.
• Reimbursement. The $1,000 maximum fair price starts in January 2027. The net effect on company revenue cannot be measured from the list price reduction alone.
• Patents and generics. The Norwich ruling covers one application. The 2028 settlement date and the unresolved proceedings remain central to the cash flow curve.
• Leverage and refinancing. $7,960 million of parent principal falls due from 2028 to 2030. Asset value does not guarantee cash in the right legal entity at the right time.
• The Bausch + Lomb stake. 68.3% of it was pledged under the 2025 financing. Minority holders, tax structure, its own leverage and its share price all limit what the stake is worth to the parent.
• Replacement. RED-C failed twice. Larsucosterol is investigational and still costs money.
• Accounting. Conventional free cash flow misses interest charged against debt premiums, and the $13 million difference between the two H1 figures is unresolved.
• Dilution and legacy claims. A distressed equity raise could fund survival while harming existing holders, and the $200 million reserve is not a verified worst case.

I assign no probability to any of these, and the price does not prove they are all discounted.

Management execution

The record is mixed. Management raised 2026 guidance, parent operations improved, and the refinancing program bought time. Against that, the 2025 debt exchanges are financing, not repayment of operating debt, the new debt is more expensive, the separation of Bausch + Lomb is unfinished, and a $1,426 million goodwill impairment landed in the first half. The failed RED-C program reduces confidence in automatic pipeline replacement, though it does not suggest anything was concealed. I assert no fraud, covenant breach or imminent insolvency. Assessment: 5/10, mixed. The next test is the third quarter report on October 28, 2026, which should show parent cash and debt, cash after all interest and any funding plan for 2028.

Stock Analyza scorecard

A zero for missing proof is an evidence penalty, not a claim that returns are zero. A clean, acquisition-adjusted return on invested capital is not available, and the cliff makes a straight-line growth series meaningless. Business quality is 36/100:

The valuation score is rated on five of six components, 47/90, and I do not rescale it to 100 or invent the missing historical part:

Apparent undervaluation and weak protection against loss are different observations, and the numeric valuation bands are not applied to an incomplete total.

Confidence score

Primary filings are available, but October balances and critical commercial details such as the net Medicare effect are missing. Predictability is lowest because patents, reimbursement and litigation all run on someone else's calendar. The Base methods agree, but the equity is highly sensitive to inputs and the Bull case diverges. Scenario dispersion is lowest because the Bear is zero and the Bull is wide. The score is what the components add up to, and I do not infer a bankruptcy from it. Positive operating cash does not remove refinancing risk.

What I would watch from here

On the evidence I have, no line is red today. The risk is that many are yellow at the same time. Normalized parent leverage is 4.69x before stock pay, which is yellow. The $1,300 million of normalized cash is at the green threshold but not yet reconciled, so it is yellow. The BLCO price of $17.30 is at the edge of the yellow band, not above it. Maturity funding for 2028 is not documented in what I have read, the Xifaxan net impact has a direction and no size, the generic proceedings, including Norwich II and Amneal with a March 10, 2026 summary judgment motion and no trial date, are unresolved, and the premium interest gap is open. Base agreement between the two methods is green, the Bull gap of 50.8% is not. The next hard date is the third quarter report on October 28.

The three most important thesis breakers

1. Post-cliff cash cannot fund or refinance the parent's obligations on terms that leave common equity something. A 20% cut to Base cash flow leaves $3.70, and a 40% cut leaves nothing.
2. The Bausch + Lomb stake cannot be turned into value for Bausch Health shareholders, because of the pledge, taxes, minority holders or creditors capturing the proceeds. A haircut of 20% instead of 10% takes the Base to $8.21 and a BLCO price of $12 to $5.82.
3. On the upside, a quantified Xifaxan bridge showing slower net erosion, together with a funded 2028 to 2030 maturity plan, would move the stock toward Undervalued and require a new valuation. One good quarter or one favorable court ruling does not do that alone.

Adversarial review

Inputs were checked against Bausch Health's Form 10-Q for the quarter ended June 30, 2026, the July 29 earnings release and its reconciliations, Bausch + Lomb's 10-Q, the CMS fact sheet on negotiated prices for 2027, and market data on the closing price. I read directly: the closing prices of $6.04 for BHC and $17.30 for BLCO on October 9; the 373,990,561 shares; the $1,825 million of cash; the first half and second quarter income statement and cash flow items; the $1,426 million impairment; the 2026 guidance ranges; the first half and second quarter stock compensation ($106 million and $54 million consolidated, $72 million and $38 million at Bausch + Lomb); the second quarter parent adjusted operating cash flow reconciliation; the 310,449,643 shares held in Bausch + Lomb; and the Xifaxan maximum fair price and list price. Every table was recomputed independently, and the figures here reproduce to the cent. Price data after the close, which showed BHC lower and BLCO higher, are excluded.

The first draft of this analysis did not deduct stock compensation from EBITDA or cash flow, on the argument that diluted shares already cover it. That is not enough here, because the share count only includes units already granted, about 17.4 million, while stock pay is a recurring cost. The parent's share, $68 million a year (my estimate), is now deducted, and Bausch + Lomb's is left in its share price. The draft also cited an appeals court result of June 26, 2026, which I could not confirm and have replaced with the April 2024 Federal Circuit ruling. The draft's external price and analyst target references are not used.

The values marked as estimates are: the multiples of 3.0x, 4.5x and 6.0x; the recurring item deductions of $150 to $200 million; the parent stock pay of $55 to $80 million a year; the Bausch + Lomb price and haircut assumptions; the $200 million legacy reserve; the 395 million share count; the FCFF bridge with its tax, reinvestment and working capital allowances; the discount rates and terminal growth; the $1,350 million cash interest allowance; and all pipeline inputs. Not available to me: October cash, debt and share counts; net Medicare exposure and generic residual economics; a verified peer multiple table; a synchronized EV to EBITDA history; consensus cash flow; the sufficiency of the legacy reserve; and the mechanics of monetizing the stake. I carried the debt principal split, the maturity schedule, the award counts, the 85% Xifaxan mix, the pledge count, the premium interest components and the legal timeline from the company's filings as summarized in the analysis, and I did not re-read each one.

The weakest points are the stake and the cash flow curve. The stake enters both methods the same way, so agreement on the Base does not test it, and the Base cash flow curve is my construction, not company guidance. The $13 million difference between the two premium interest figures is worth at most $0.033 a share if it is a one-time cash difference, but it is unresolved. The larger commercial and financing uncertainties are why Confidence is D, no buy zone is issued and no pipeline value is added. A conservative assumption does not prove an uncertainty has been solved. The publication gate status is PASS WITH WARNING for a conditional research report, and FAIL for an unqualified buy or a precise fair value.

Final verdict: hold at $6.04, no new buy

Bausch Health has a good 2026 and a harder 2028. Parent cash of about $1.3 billion this year covers 54.5% of the market value, but my estimate of the same cash after $1.35 billion of interest and the Xifaxan cliff is about $50 million in 2030. The market already knows: it prices the parent at 3.97x EBITDA after stock pay, about 15% of Base cash below my Base. That leaves the shares 36.9% below Base on paper, with a zero in the Bear case.

Verdict: HOLD at $6.04, watchlist, no new buy. Triangulated Base value $9.57, upside 58.5%, Confidence D (10/25). The required 70% margin of safety exceeds the framework's practical ceiling, so no maximum buy price is issued.

The 54% yield is a 2026 number. The equity is a 2030 question.

Sources

Primary sources include Bausch Health's Form 10-Q for the quarter ended June 30, 2026 (balance sheet, share count, cash flows, stock compensation, impairment and legal proceedings), the July 29, 2026 earnings release and reconciliations (guidance, adjusted EBITDA, parent adjusted operating cash flow and stock compensation add-backs) and Bausch + Lomb's Form 10-Q for the same quarter (cash, cash flow, stock compensation and the shares held by Bausch Health). The Medicare prices come from the CMS fact sheet on negotiated prices for 2027. The 2024 Norwich ruling is reported in a Yahoo News report of April 11, 2024. The company's 2025 annual report supplies the annual cash flow series and the financing and pledge disclosure, and the investor relations site the guidance and the October 28 earnings date. Closing prices come from StockAnalysis for BHC and StockAnalysis for BLCO.

The reference market price is the October 9, 2026 regular session close of $6.04. Cash, debt and maturities are as of June 30, 2026, and shares as of July 24, 2026. Third quarter results were not yet available. The multiples, forecasts, allowances, stock pay run rate, discount rates, stake haircut, reserve and pipeline inputs are analytical estimates, not company guidance.